Layer-by-layer assembled fluorescent probes in the second near-infrared window for systemic delivery and detection of ovarian cancer by Dang, Xiangnan et al.
Layer-by-layer assembled fluorescent probes in the
second near-infrared window for systemic delivery
and detection of ovarian cancer
Xiangnan Danga,b,1, Li Gua,c,1, Jifa Qia,b, Santiago Correaa,d, Geran Zhanga,b, Angela M. Belchera,b,d,2,
and Paula T. Hammonda,c,2
aKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139; bDepartment of Materials Science and
Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; cDepartment of Chemical Engineering, Massachusetts Institute of Technology,
Cambridge, MA 02139; and dDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139
Edited by Michelle Bradbury, Memorial Sloan Kettering, New York, NY, and accepted by the Editorial Board March 14, 2016 (received for review October
27, 2015)
Fluorescence imaging in the second near-infrared window (NIR-II,
1,000–1,700 nm) features deep tissue penetration, reduced tissue
scattering, and diminishing tissue autofluorescence. Here, NIR-II
fluorescent probes, including down-conversion nanoparticles, quan-
tum dots, single-walled carbon nanotubes, and organic dyes, are
constructed into biocompatible nanoparticles using the layer-by-
layer (LbL) platform due to its modular and versatile nature. The
LbL platform has previously been demonstrated to enable incor-
poration of diagnostic agents, drugs, and nucleic acids such as
siRNA while providing enhanced blood plasma half-life and tumor
targeting. This work carries out head-to-head comparisons of cur-
rently available NIR-II probes with identical LbL coatings with
regard to their biodistribution, pharmacokinetics, and toxicities.
Overall, rare-earth-based down-conversion nanoparticles demon-
strate optimal biological and optical performance and are evalu-
ated as a diagnostic probe for high-grade serous ovarian cancer,
typically diagnosed at late stage. Successful detection of ortho-
topic ovarian tumors is achieved by in vivo NIR-II imaging and
confirmed by ex vivo microscopic imaging. Collectively, these re-
sults indicate that LbL-based NIR-II probes can serve as a promising
theranostic platform to effectively and noninvasively monitor the
progression and treatment of serous ovarian cancer.
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Fluorescence-based optical imaging is a broadly applied im-aging technique that provides a nondestructive means for
detecting disease, monitoring disease progression, and evaluating
treatment outcome (1–4). Compared with tomographic imaging
techniques, such as magnetic resonance imaging and computed
tomography, fluorescence imaging yields quicker results at a lower
cost (5). Fluorescence imaging is categorized according to the
spectral regions of the detected signal, including visible (400–
750 nm), the first near-infrared window (NIR-I, 750–1,000 nm), and
the second near-infrared window (NIR-II; 1,000–1,700 nm). NIR-II
fluorescence imaging features deeper penetration and outperforms
the others for in vivo investigations owing to the reduced absorp-
tion, scattering, and autofluorescence by biological tissues (6, 7).
To clinically translate the benefits of NIR-II imaging, several
challenges associated with the delivery of nanoscale NIR-II
probes need to be addressed: (i) the biocompatibility following
systemic administration of NIR-II probes in vivo, (ii) a delivery
platform that extends the blood circulation time of NIR-II probes
to facilitate accumulation in diseased tissues and sustained signal
detection, and (iii) the successful targeting of NIR-II probes to
sites of biomedical interest to provide enhanced diagnostic func-
tionality. Current NIR-II emissive materials, including rare-earth-
based down-conversion nanoparticles (DCNPs), quantum dots
(QDs), single-walled carbon nanotubes (SWNTs), and small or-
ganic molecules, have been incorporated into diagnostic probes
using a single lipid, polymer, protein, or bacteriophage (6–12).
However, these delivery carriers lack the modularity and versatility
to include drugs effectively for theranostic platforms and do not as
readily enable the incorporation of complex or multiple drug
payloads. Consequently, a modular delivery system of the NIR-II
probes is more attractive because it allows incorporation of im-
aging agents and multiple drugs independently and ability of
staged release of therapeutics.
Layer-by-layer (LbL) assembly is a well-established technology
that matches the requirements for modularity and versatility to
develop theranostic platforms for different NIR-II probes. LbL
assembly allows for the construction of hierarchical and multi-
functional polyelectrolyte multilayers on a charged colloidal core
substrate (13–15), and it is possible to incorporate therapeutics such
as siRNA, inhibitors, or proteins in the multilayers around the core
nanoparticle (NP) (16). The LbL platform provides improved
biocompatibility that reduces off-target toxicity of the delivered
payloads (17), and the LbL stealth coatings provide extended
blood plasma half-life when applied to liposomes, QDs, gold, and
other NP systems (15, 18). Recent work using the LbL platform
has led to a demonstration of staged siRNA/chemotherapy
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combination release in a triple-negative breast cancer model
(13). Furthermore, the LbL system can be used to generate
highly effective, dual targeting of outer layers that enables ac-
cumulation both through stimuli-responsive behavior triggered
by the hypoxic tumor microenvironment and through the binding
of ligands overexpressed on tumor cell membranes (14). The
considerable control and flexibility of the LbL platform makes it
ideal for preparing theranostic nanomedicines, because it can
load both therapeutics and diagnostics with high capacity (19, 20)
and can coat a broad range of nanomaterials down to 10 nm in
size while maintaining uniformity, shape, and structure (18).
Despite current efforts of applying NIR-II probes for bio-
imaging, some of the essential properties relevant for the clinical
translation of these probes are either missing or insufficiently
characterized for in vivo biomedical applications. Particularly,
SWNTs suffer from poor circulation in either lipid-coated or
bacteriophage-bound form (11, 21), the pharmacokinetics of NIR-
II emissive QDs and organic dyes are rarely reported (8, 10), and
real-time whole-body imaging and pharmacokinetics for DCNPs
are not reported (9). Furthermore, each material was studied with
different delivery systems and instrumentation, contributing to the
observed variations in performance across reports. Therefore, we
leverage the LbL platform to generate NIR-II probes with a re-
producible and biocompatible targeting stealth coating to facilitate
the head-to-head comparison of these materials in vivo.
In this paper, we generate LbL NIR-II NPs with identical
polymer multilayer modifications to provide a comprehensive
side-by-side evaluation of the available NIR-II materials for
in vivo real-time whole-body circulation, pharmacokinetics, bio-
distribution, toxicities, and applications in disease detection.
Different LbL NIR-II NPs broadly exhibit prolonged blood cir-
culation, a critical factor that allows NPs to accumulate in dis-
eased sites. Comparison of these NPs affords clinically relevant
information on currently available NIR-II probes and reveals
their benefits and drawbacks, providing guidance for potential
clinical translation. Overall, LbL-modified DCNPs exhibit ex-
cellent signal-to-noise ratio, low toxicity, and long circulation and
are selected to demonstrate diagnostic capabilities within ovar-
ian tumor, typically diagnosed at advanced stage. Both in vivo
imaging and histology of the diseased tissues suggest preferential
accumulation of LbL DCNPs in the tumors, indicating that LbL
NIR-II NPs may act as an effective diagnostic platform. More-
over, the modular nature of the LbL platform allows us to fur-
ther functionalize these materials, particularly through the
incorporation of therapeutics to transform the formulations
discussed in this work into theranostic NPs.
Results and Discussion
Preparation and Characterization of LbL NIR-II NPs. LbL NPs were
constructed for NIR-II probes, including an organic dye
(IR1061), SWNT, QD (PbS), and DCNP (NaY0.78Yb0.2Er0.02F4)
(Fig. 1 A and B). Each of the hydrophobic nanoscale NIR-II
probes (dye, QD, and DCNP) was first encapsulated in the
amphiphilic partially alkyl amide functionalized poly(acrylic
acid) (PAA) to yield a net negatively charged core (∼100 nm in
diameter) for LbL assembly. In the case of the SWNT system, a
negatively charged core was first created using sodium cholate
stabilized SWNTs to undergo ligand exchange with the modified
PAA. Biocompatible poly(L-arginine) (PLA, 10 kDa) and dex-
tran sulfate (DXS, 10 kDa) were the barrier layers. Hyaluronic
acid (HA, 40 kDa) for the outmost layer is a natural poly-
saccharide that extends blood circulation, targets CD44 (a largely
expressed receptor in many cancer cell lines), and provides tun-
able surface chemistry for further modifications. Successful LbL
assembly was confirmed by dynamic light scattering (DLS) size
measurements that indicated a 10-nm growth following the de-
position of each barrier layer and a 40-nm growth following the
deposition of terminal HA layer (Fig. 1C). Further validation of
layer deposition was provided by electrophoretic measurements
that indicated a complete reversal of surface charge following each
layer deposition (Fig. 1C). The completed LbL NPs, with a layered
structure consisting of NIR-II emissive core/PLA/DXS/PLA/HA,
possessed zeta potentials of approximately −30 mV and hydro-
dynamic diameters within the optimal range (10–200 nm) for
systemic delivery (22, 23), except the SWNT (280 nm) because its
unique elongated shape was not recognized correctly by DLS
measurement. Whereas the polydispersity index (PDI) of dye,
QD, and DCNP systems falls between 0.1 and 0.2, indicating
monodisperse LbL NPs, the higher PDI of 0.3 for LbL SWNTs
was owing to the variation in length of the starting SWNTs (Fig.
1C). In addition, transmission electron microscopy (TEM) con-
firmed the layered structure of LbL NPs (Fig. 1B). A thin LbL
polyelectrolyte complex coating was observed for each of the three
spherical NPs; it should be noted that the LbL films consist of
highly interpenetrated carbon-based polyion blends, and thus in-
dividual polyelectrolyte layers were indistinguishable in TEM.
SWNTs of 3 nm in diameter were observed as singular nanotubes
on a holey grid after LbL assembly, indicating that nanotubes
presented primarily as individual rather than aggregate structures.
It was suggested that the charged SWNTs remained sterically
stabilized during LbL assembly, thus retaining efficient fluores-
cence. Before studying the LbL NIR-II NPs for in vivo imaging,
optical absorption and emission spectra were measured (Fig. 1 D
and E and Fig. S1). NIR-II probes were excited with either an 808-nm
or a 980-nm laser depending on the unique excitation properties
of each probe, while maintaining a large spectral separation
between excitation wavelengths and main emission peaks (SI
Results and Discussion and Fig. S2). The excitation wavelengths
and emission peaks (shown as λex/λem in nanometers) of LbL
NPs were 808/1,100 for dye complex, 808/1,225 for SWNT, 980/
1,350 for QD, and 980/1,575 for DCNP system (Fig. 1E). Under
these excitation and emission conditions, the dye complex
(3,285 cm−1) and QD (2,797 cm−1) possessed smaller Stokes shift
than the SWNT (4,213 cm−1) and DCNP (3,855 cm−1) systems.
Biodistribution and Pharmacokinetics of LbL NIR-II NPs. To evaluate
and compare the different LbL-coated NIR-II probes for
Fig. 1. Characterization of the LbL NIR-II NPs. (A) Illustration of a spherical LbL
NIR-II NP. From inside to outside: NIR-II core (red), PLA (blue), DXS (yellow), PLA
(blue), and HA (green). (B) TEM images of the LbL NIR-II NPs. [Scale bars: 50 nm
(5 nm for SWNT).] (C) DLS characterizations of the NPs for each LbL step, in-
cluding hydrodynamic diameter, zeta potential, and PDI. Data are given inmean ±
SD, n = 3. (D and E) Normalized absorption (D) and emission (E) spectra of the NPs.
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biomedical applications, biodistribution and pharmacokinetics
studies of each LbL NP type were performed in BALB/c female
mice. Whole-body real-time fluorescence imaging was carried
out using a custom-built imager, consisting of 808-nm and 980-nm
lasers, a silicon camera for bright-field images, and an InGaAs
camera taking NIR-II fluorescence images. During whole-body
imaging, mice were placed under anesthesia and arranged in ei-
ther the dorsal or lateral position and injected with LbL NPs via a
catheterized tail vein. Immediately following the bolus injections
of the NPs, fluorescence images were acquired continuously for
5 min; during this immediate time period, because the NPs were
introduced rapidly throughout the bloodstream most organs were
clearly recognized (Movie S1, with play speed 10× faster). To
study the long-term distributions of the NPs, the whole-body
bright-field and fluorescence images were collected at multiple
time points ranging from 5 min to 72 h postinjection (Fig. 2A). At
the same time points, blood samples were drawn and analyzed
to assess NP pharmacokinetics (Fig. 2D). Additionally, time-
dependent biodistribution of LbL NPs was quantified from
injection to 72 h postinjection based on the in vivo fluorescence
images (Fig. 2E), and end-point ex vivo biodistribution was
quantified based on the fluorescence images of the harvested
organs at 72 h postinjection (Fig. 2F).
Several similar features of the biodistribution and pharmaco-
kinetics were observed among the LbL NIR-II NPs. For the
biodistribution study, the NPs localized to the heart within 10 s
and began to accumulate in the lungs, liver, spleen, and circu-
latory system at ∼30 s (Movie S1 and Fig. 2E). The fluorescence
intensities of various major organs remained relatively stable
during the remaining part of the video and for up to 1 h. At later
time points, fluorescent signals decayed in the major organs for
most of the LbL NPs except dye, indicating the clearance of the
Fig. 2. The biodistribution, pharmacokinetics, and optical properties of LbL NIR-II NPs following i.v. injection in BALB/c mice. (A) Whole-body NIR-II images at time
points from 10 s to 72 h postinjection. For the first three time points, NIR-II images were extracted from the videos (Movie S1) at lateral (Left) and dorsal (Right)
positions, and for the later time points NIR-II and bright-field images were taken at ventral (Left), lateral (Middle), and dorsal (Right) positions. From left to right
and top to bottom, organs were presented in the order of heart, lungs, spine, spleen, liver, stomach, kidneys, intestines, and pancreas. (B) The scattering widths of
NIR-II signals (Left) as a function of the penetration depth through breast-mimic phantoms (Right, scheme of the experimental setup and a typical image showing
the scattering effect). (C) The signal-to-autofluorescence ratios of various NIR-II probes (Left) were quantified based on the fluorescence intensities of liver and
abdominal cavity (the elliptical area, Right); the outline of the mouse is shown as a white dotted line. Data are given as mean + SD, n = 5. (D) The blood circulation
profiles and fitted half-lives using a two-compartment decay model. Data are given as mean ± SD, n = 3. (E) The dynamic distribution profiles of the LbL NPs in
major organs based on the fluorescence intensities from injection time to 72 h postinjection. The intensities up to 5 min (shown as lines) were extracted from the
videos, and intensities at later time points (shown as lines and symbols, mean value from three to five measurements) were extracted from the NIR-II images.
(F) The distribution profiles of NPs in the excised organs based on the fluorescence intensities at 72 h postinjection. Data are given as mean + SD, n ≥ 5.


















NPs prevailed over their accumulation. As expected, the liver
and spleen were the main sources of fluorescent signals over the
72-h treatment period (Fig. 2F), consistent with the role of these
organs in the reticuloendothelial system. Interestingly, NP ac-
cumulation was observed in osseous tissues from 30 s to 48 h
postinjection, including the spine, femur, and tibia (Fig. 2A).
Tracking of NPs to osseous tissues demonstrated the benefit of
deep penetration gained with NIR-II imaging, because it was
difficult to observe with visible and NIR-I imaging.
The pharmacokinetic analysis of the LbL NPs indicated that
the probe concentrations in blood experienced a two-phase de-
cay, including the processes of initial rapid distribution and fol-
lowing elimination from tissues. Notably, all LbL NPs, with the
exception of the QD system, possessed extended half-lives as
long as 24 h (Fig. 2D), likely owing to the role of the highly
hydrophilic terminal HA layer preventing protein adsorption and
opsonization, and the formation of a particularly dense layer in
LbL systems achieved upon adsorption to the underlying PLA
layer. We have previously examined these PLA/HA systems and
found that these extended half-lives were characteristic of weak
LbL systems with HA (13, 14, 17). The similarities observed for
different NIR-II NPs were likely attributable to the identical LbL
surface modifications and demonstrated the efficacy of the LbL
platform for facilitating the systemic delivery of diverse material
systems. It is noted that the serum stability of the LbL coatings
on the surfaces of these very different NIR-II probes is key to
achieving the long-term blood circulation required for systemic
applications, particularly when examining accumulations that can
take place over a period of several days (Fig. S3). The QD sys-
tem, however, had a half-life of 9 h, much shorter than that of the
other systems and different from our observations of LbL QD
systems examined in earlier work (15). We believe this difference
may be related to the nature of the modified PAA coating on the
QD surface, which may not have formed as cohesive an interface
with the LbL layers as that achieved with direct layering of a QD
synthesized with negatively charged ligands.
Despite the common characteristics among the LbL NIR-II
NPs, unique features were observed for each probe. First, for
LbL DCNPs at 72 h postinjection, fluorescence intensities were
predominantly detected in liver and spleen both in vivo and ex
vivo, and the relative intensities from other organs were much
lower than those from the other probes, in part due to the long
emission wavelength of DCNP, further explained in the next
section (Fig. 2F). Second, LbL SWNTs exhibited the quickest
first-phase decay from blood circulation (0.1 h), followed by a
slow second-phase decay (24.1 h) (Fig. 2D), in accordance with
their rapid initial accumulation and sluggish clearance from the
major organs (Fig. 2E). For instance, osseous organs including
sternum, femur, and spine were identified at as late as 48 h
postinjection (Fig. 2A), and the relative fluorescence intensities
of SWNTs in excised organs were higher than those of DCNPs
(Fig. 2F). This was attributed to the elongated shape of SWNTs,
which may promote tissue penetration and therefore rapidly
reduce the concentration of SWNTs in the circulatory system
immediately after injection, as well as promote entrapment by
the organs to slow excretion from tissues. Third, in contrast to
SWNTs, LbL QDs exhibited the slowest first-phase decay (0.63 h)
and fastest second-phase decay (9.77 h) (Fig. 2D), in agreement
with the extended ascending and sudden descending fluorescence
profiles of the major organs (Fig. 2E). In addition, QDs exhibited
the lowest fluorescence intensities in the harvested organs (Fig.
2F). Based on previous reports (24, 25), it is thought that QDs
(∼6 nm), first encapsulated in amphiphilic PAA, can diffuse out of
the LbL film and eventually be cleared via the renal system (26,
27). Finally, the LbL dye complex presented an unusual fluores-
cence profile of the organs, in which the fluorescence intensity
peaked at ∼24 h postinjection (Fig. 2E), suggesting that the dye
complex maintained a high concentration in the blood (Fig. 2D)
and continuously accumulated in the organs for a long time before
tissue clearance dominated. It was concluded that, among these
LbL NIR-II NPs, DCNPs exhibited the most favorable bio-
distribution and pharmacokinetics profile, because they offered
prolonged first- and second-phase decays, as well as a regular
pattern of tissue clearance.
The distinguishing optical properties of various NIR-II probes
likely contributed to the observed discrepancies for in vivo and
ex vivo fluorescence imaging. In general, probes with longer
emission wavelengths can be imaged with higher quality owing to
reduced light scattering and tissue autofluorescence. In partic-
ular, light scattering decreases monotonically as emission wave-
length increases (9, 28, 29). According to their fluorescence
emission spectra, we chose optical filter sets of two 1,400-nm
long pass + two 1,575-nm band pass, two 1,300-nm long pass + two
1,375-nm band pass, two 1,300-nm long pass, and two 1,100-nm
long pass + two 1,125-nm band pass for DCNPs, QDs, SWNTs, and
dye complex, respectively, to maximize each probe’s signal-to-noise
ratio (Table S1). As a result, LbL DCNPs offered NIR-II images
with the least scattering and correspondingly defined the vascular
and skeletal structures with the highest resolution out of all of the
probes (Movie S1 and Fig. 2A).
The different scattering of fluorescent signals emitted by NIR-
II probes was further investigated using breast-mimic phantoms
of various thicknesses. It was observed that the degree of scat-
tering decreased as the emission spectra moved toward longer
wavelengths (Fig. 2B). The other major source of background
noise is autofluorescence, which is known to decrease with larger
spectral separation between excitation and emission wave-
lengths. As mentioned previously, DCNPs and SWNTs process
Stokes shift close to or larger than 4,000 cm−1, which is out of the
range of the Raman shift of most organic molecules, providing
the low level of autofluorescence observed with these probes (30,
31). Instead, QDs and dye complex possess Stokes shift around
3,000 cm−1, strongly overlapping with the Raman shift of organic
molecules, resulting in greater autofluorescence, especially in the
regions of abdominal cavity and skin (Fig. 2 A and C). In addi-
tion, the excitation wavelength of 808 nm (for dye or SWNTs)
resulted in more autofluorescence than the excitation wavelength
of 980 nm (for QDs or DCNPs), albeit with similar Raman shift
(dye and QDs, or SWNTs and DCNPs), because Raman intensity
is inversely proportional to the fourth power of the excitation
wavelength (32). The high level of autofluorescence observed for
NIR-II imaging with the dye complex likely contributed to the
irregular fluorescent signal profiles and low quality of images (Fig.
2 A and E and Movie S1), as well as the highest fluorescence in-
tensities from excised organs (Fig. 2F). Overall, LbL DCNPs of-
fered the optimal optical properties for NIR-II imaging, with the
least interference from scattering and autofluorescence, and
seemed to be a promising tool for biomedical imaging.
To the best of our knowledge, this is the first report to provide
a comprehensive investigation as well as comparison of the
biodistribution and pharmacokinetics of the currently available
NIR-II fluorescent probes. Further, it is a first look, to our
knowledge, at the potential for LbL coatings to address the en-
hancement of biodistribution for each of four very different NIR-II
emissive material systems. All NIR-II probes possessed identical
LbL modifications and allowed us to attribute the similarities and
differences across these probes to their intrinsic characteristics,
morphological or optical. In contrast, the observed variations of
performance from different probes among previous reports could
be partly owing to extrinsic properties, such as surface charge,
surface chemistry, or targeting ligands.
To assess the capabilities of NIR-II imaging to obtain ana-
tomical information, principle component analysis (PCA) was
performed to group image pixels with similar time-dependent
fluorescence intensities (33). PCA of the video frames of first
5 min postinjection generated composite images that distinguished
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various organs with different assigned colors (Fig. 3). For all LbL
NIR-II NPs, the main clearance organs (lungs, liver, and spleen)
were the major ones identified. Although PCA of SWNTs, QDs,
and dye systems showed organ resolution comparable to pre-
vious reports (8, 10, 33), video-rate whole-body imaging imme-
diately following i.v. injection of LbL DCNPs and associated
PCA is, to our knowledge, first reported in this study. Further,
PCA of DCNPs system produced clearer anatomical features, as
well as more identified organs, such as pancreas, skin vascular
network, and spine, due to the advantages of longer emission
wavelength such as deeper penetration, less light scattering, and
reduced autofluorescence.
Toxicities of LbL NIR-II NPs. To evaluate the toxicities of the LbL
NPs in vivo, the vital organs, including liver, spleen, heart, lungs,
and kidneys, were excised and fixed with formalin at 72 h post-
injection. Standard H&E staining of the major organs’ cross-
sections was performed. As examples show in Fig. S4, for tissues
from mice treated with all of the probes (i) cardiac fibers in the
hearts maintained integrity; (ii) white pulps, red pulps, and tra-
becular arteries in the spleens were observed without major
damage; and (iii) irregular macrophage accumulation in the
lungs was not observed in the alveolus space, indicating that LbL
NPs did not trigger a severe immune response. In addition, no
major damage in the liver or kidneys was observed in mice
treated with the dye, SWNTs, and DCNPs systems. However,
severe toxicities in liver and kidneys were detected in QDs-
treated mice. For instance, focal necrosis and dilated hepato-
cytes were identified in the liver (circled in Fig. S4C), and
swollen tubule, a sign of kidney atrophy, was also noted (Fig.
S4C). Hepato-renal toxicity is a well-known issue preventing the
approval of QDs for biomedical applications, and the observed
damage is likely attributed to the leakage of the QDs out of the
LbL shell (34, 35). To our knowledge, this is the first report of
the head-to-head comparison of toxicities of NIR-II probes in an
identical LbL platform. In summary, we observed that the LbL-
modified dye complex, SWNTs, and DCNPs were functionally
nontoxic for biomedical applications. In contrast, these LbL QDs
presented severe tissue toxicities; however, past work with LbL
QDs suggests that this toxicity is related to leakage of individual
QDs from the inner modified PAA encapsulation and LbL films
(24, 25, 36).
Detection of Orthotopic Ovarian Tumors Using LbL DCNPs. Owing to
their superior biodistribution, pharmacokinetics, and optical
properties, LbL DCNPs were used to detect the presence of
ovarian tumors in an orthotopic murine model. In this study,
COV362 cells were selected based on their genetic similarity to
high-grade serous ovarian cancer (HGSOC), the most aggressive
ovarian carcinoma subtype (37). The orthotopic tumors were
typically formed and disseminated in the cavity after 2 wk fol-
lowing the i.p. implantation of cancer cells into the nude mice.
To detect the tumors, the mice received LbL DCNPs as a single
i.p. dose. NIR-II fluorescence images of the whole body and
excised organs were captured at 72 h postinjection, showing in-
dividual disseminated tumor nodules and tumor nodes on nor-
mal tissues (Fig. 4A and Fig. S5; the bright spots indicate the
location of the tumors). Tumors and organs of interest were
extracted, fixed with formalin, and stained with H&E. The for-
mation of orthotopic ovarian tumors was confirmed by histo-
pathological features such as irregular cellular shape and
crowding, high nuclear-to-cytoplasmic ratio, and a distinct ne-
crotic core (Fig. 4B) (7). Furthermore, up-converted visible light
by DCNPs (38) allowed us to determine the colocalization of
DCNPs and tumorous tissue on the cellular level using two-
photon confocal microscopy. The DCNPs were found pre-
dominantly in the tumor nodes (Fig. 4B), which preferentially
uptook LbL DCNPs relative to normal tissues such as the pan-
creas and intestine (Fig. 4 C and D). The selectivity is likely due
to the HA terminal layer, which binds to the CD44 receptor
overexpressed by the COV362 cell line. Notably, in certain in-
stances tumor cell crowding was observed inside the liver, in-
dicative of tumor invasion, where relatively fewer DCNPs were
detected in the tumor area (Fig. 4E). To our knowledge, this
approach to determine colocalization of NPs and tumorous tissue
on the cellular level using any other NIR-II probes has not been
reported, because most intravital confocal microscopes are not
equipped with necessary NIR-II detectors. Instead, DCNPs offer
up-converted visible emission for cellular-level detection with
low autofluorescence and down-converted NIR-II emission for in
vivo imaging with deep penetration. Herein, we provide the first
Fig. 3. (A–D) PCA of the videos acquired from in-
jection time to 5 min postinjection. For each type of
NPs, the lateral (Left) and dorsal (Right) positions are
shown. For each composite image, the red, green,
and blue channels represent the combined positive
and negative areas of the second, third, and fourth
principle components, respectively, from PCA.
Fig. 4. Targeted detection of orthotopic ovarian tu-
mors. (A) NIR-II images of the whole mouse (left) and
the excised organs (from left to right and top to bot-
tom are, spleen, ovaries, kidneys, pancreas, liver,
stomach, and intestines). The bright spots indicate tu-
mor nodules. (B–E) Slices of tumor (B), tumor nodules
on pancreas (C), intestine (D), and the tumor invaded
the liver (E). Each pair show an H&E-stained slice of
tissue (Left) and the registered multiphoton confocal
microscopy (Right) where signals from DCNPs (green),
hematoxylin (blue), and eosin (red) were composited.
(Scale bars: 100 μm.)


















proof-of-concept study, to our knowledge, using LbL DCNPs for
cancer detection in an HGSOC model and demonstrate the ef-
fectiveness and versatility of these modular systems for promising
translational applications, from bioimaging to theranostics.
Conclusion. In summary, we constructed LbL-modified NIR-II
NPs from currently available NIR-II fluorescent materials to
perform a side-by-side investigation and comparison for the
biodistribution, pharmacokinetics, and toxicities of these probes.
Despite prior research efforts, many benefits and drawbacks
among current NIR-II probes remained unexplored. For the first
time to our knowledge, these NIR-II probes were directly com-
pared to determine clinically relevant information using the
same delivery platform and imaging instrumentation, eliminating
previously observed discrepancies generated by such external
factors. As a consequence, the findings and achievements in this
study are of great interest for research endeavors in NIR-II
imaging and provide guidance when applying NIR-II fluorescent
probes for biomedical applications.
After weighing both the optical and the pharmacokinetic
characteristics of these NIR-II probes, LbL-modified DCNPs
provided superior imaging performance and were evaluated as a
diagnostic tool in an orthotopic model of HGSOC. The ovarian
tumors, either distributed within the abdominal cavity or associ-
ated with vital organs such as liver, pancreas, intestine, and so on,
were successfully detected in a noninvasive manner. This study
concludes that LbL NIR-II NPs can serve as an imaging tool to
monitor tumor dissemination, invasion, metastasis, and treatment
response, as well as real-time imaging-guided surgery.
Materials and Methods
All materials are provided in SI Materials and Methods. Experimental pro-
cedures are provided in SI Materials and Methods, including synthesis of
DCNPs and SWNTs, fabrication and characterization of LbL NIR-II NPs, mouse
handling and injection, whole-body imaging, pharmacokinetics, toxicity, cell
culture, and tumor induction procedures, calculation of scattering width and
signal-to-autofluorescence ratio, PCA, and multiphoton confocal microscopy.
All in vivo experiments were performed under the supervision of the
Division of Comparative Medicine, Massachusetts Institute of Technology,
and in compliance with the principles of laboratory animal care of the Na-
tional Institutes of Health.
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